KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesBeginning Cash BalanceCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Net Cash Flow: 2011-2024

Historic Net Cash Flow for Esperion Therapeutics (ESPR) over the last 14 years, with Dec 2024 value amounting to $62.5 million.

  • Esperion Therapeutics' Net Cash Flow rose 114.32% to $6.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$52.3 million, marking a year-over-year decrease of 274.91%. This contributed to the annual value of $62.5 million for FY2024, which is 247.00% up from last year.
  • As of FY2024, Esperion Therapeutics' Net Cash Flow stood at $62.5 million, which was up 247.00% from -$42.5 million recorded in FY2023.
  • In the past 5 years, Esperion Therapeutics' Net Cash Flow registered a high of $137.9 million during FY2020, and its lowest value of -$134.1 million during FY2022.
  • Over the past 3 years, Esperion Therapeutics' median Net Cash Flow value was -$42.5 million (recorded in 2023), while the average stood at -$38.0 million.
  • In the last 5 years, Esperion Therapeutics' Net Cash Flow slumped by 191.12% in 2022 and then surged by 247.00% in 2024.
  • Over the past 5 years, Esperion Therapeutics' Net Cash Flow (Yearly) stood at $137.9 million in 2020, then tumbled by 133.41% to -$46.1 million in 2021, then crashed by 191.12% to -$134.1 million in 2022, then skyrocketed by 68.29% to -$42.5 million in 2023, then soared by 247.00% to $62.5 million in 2024.